Clinical
The registry entry for the poziotinib study in HER2 exon 20-mutated lung cancer now reads SUSPENDED, with no patients enrolled and a redesign under discussion with the FDA.
HRMY
The registry entry for Harmony's Phase 3 study of cannabidiol in Fragile X syndrome now shows a status of COMPLETED, updated 1 September 2026.
Clinical
PDS Biotechnology has terminated its Phase 3 study of PDS0101 plus pembrolizumab, citing financial constraints rather than safety concerns.
INCY
The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.